By nature, and by predisposition, this highly aggressive neuroendocrine tumor doubles rapidly and disseminates widely early on, so that 80-85% of patients are diagnosed with advanced or …

Jun 1, 2023 · Extensive-stage small-cell lung cancer (ES-SCLC) is regarded as a refractory carcinoma associated with extremely rapid disease progression. After more than three …

Here, we review current treatment options and recent progress made in the first-line and relapsed SCLC, including the role of biomarkers and new evolving therapeutic strategies. Small-cell …

Small-cell lung cancer (SCLC) is characterized by aggressive disease progression and tendency to metastasize. Although chemotherapy for extensive-stage SCLC (ES-SCLC) has remained …

Small cell lung cancer (SCLC) is a neuroendocrine tumor that represents approximately 15 percent of all lung cancers. SCLC occurs predominantly in smokers. (See "Cigarette smoking …

Oct 8, 2020 · This study used real-world data to describe treatment patterns of ES-SCLC patients in the United States following the introduction of immunotherapy (IO).

Although chemotherapy significantly improves the quality of life and prolongs survival in patients with extensive-stage small cell lung cancer (ES-SCLC), relapse is almost inevitable, with only …

May 27, 2024 · Recent progress in the treatment of extensive-stage disease (ES-SCLC) has been marked by incorporating immune checkpoint inhibitors (ICIs) into platinum-based …

5 days ago · Although chemotherapy significantly improves the quality of life and prolongs survival in patients with extensive-stage small cell lung cancer (ES-SCLC), relapse is almost inevitable, …

4 days ago · The American Journal of Managed Care (4/8, Kaltwasser) reports research indicates that “patients with extensive-stage small cell lung cancer (ES-SCLC) are more likely to have …